Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1 Recurrence 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1

Interventions

Injections 12 pembrolizumab 11 Nivolumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Cisplatin 6 Capecitabine 6 Gemcitabine 5 toripalimab 4 tislelizumab 4 atezolizumab 4 Ipilimumab 4 Carboplatin 4 Bevacizumab 4 sintilimab 3 Rifampin 3 Oxaliplatin 3 Itraconazole 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 pertuzumab 2 osimertinib 2 ontuxizumab 2 navoximod 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × ulocuplumab × Clear all

NCT02472977 2018-11-01

CXCessoR4

Bristol-Myers Squibb

Phase 1/2 Terminated

61 enrolled 11 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡